The Online Investor

Slideshow Mega-Mergers: Largest Recent M&A Transactions

By The Online Investor Staff, updated Thu., Jan. 28, 3:50 AM

Slide #1. BridgeBio Pharma, Inc. Eidos Therapeutics, Inc.

Acquirer: BridgeBio Pharma, Inc. (BBIO)
Acquiree: Eidos Therapeutics, Inc. (EIDX)
Details: BridgeBio Pharma, Inc. ("BridgeBio") (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. ("Eidos") (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own. The transaction was overwhelmingly approved by BridgeBio and Eidos stockholders.

BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipelines include: BBP-265/AG10, an oral small molecule TTR, stabilizer, for the treatment of TTR amyloidosis; BBP-831/Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical AAV, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia; and BBP-454, a preclinical development program for the treatment of KRAS-driven cancers.

BBIO SEC Filing Email Alerts Service


Open the BBIO Page at The Online Investor »

BridegeBio Pharma identifies and improves medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Co.'s pipelines include: BBP-265/AG10, an oral small molecule TTR, stabilizer, for the treatment of TTR amyloidosis; BBP-831/Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical AAV, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia; and BBP-454, a preclinical development program for the treatment of KRAS-driven cancers.

BBIO SEC Filing Email Alerts Service


Open the EIDX Page at The Online Investor »

Company Name: 
BridgeBio Pharma Inc
Website: 
www.bridgebio.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding BBIO: 
18
Total Market Value Held by ETFs: 
$562.01M
Total Market Capitalization: 
$8.06B
% of Market Cap. Held by ETFs: 
6.97%
Company Name: 
Eidos Therapeutics Inc
Website: 
www.eidostx.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding EIDX: 
22
Total Market Value Held by ETFs: 
$191.93M
Total Market Capitalization: 
$4.97B
% of Market Cap. Held by ETFs: 
3.86%
 

Quotes delayed 20 minutes


Mega-Mergers Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.